Recombinant tissue plasminogen activators (rtPA): A review
Authors:
- 31 January 2015
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 97 (3) , 274-285
Abstract
No abstract availableThis publication has 56 references indexed in Scilit:
- Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticleInternational Journal of Nanomedicine, 2012
- The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Lancet, 2012
- Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysisThe Lancet, 2012
- Frostbites in circumpolar areasGlobal Health Action, 2011
- Intra-arterial Therapy for Acute Ischemic StrokeNeurotherapeutics, 2011
- The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studiesBlood, 2011
- Basic mechanisms and pathogenesis of venous thrombosisBlood Reviews, 2009
- Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic StrokeStroke, 2009
- Review of tenecteplase (TNKase) in the treatment of acute myocardial infarctionVascular Health and Risk Management, 2009
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993